Group One Trading
DYN icon

Group One Trading’s Dyne Therapeutics DYN Stock Holding History

Group One Trading’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.8K Sell
800
-100
-11% -$1.86K ﹤0.01% 6089
2026
Q1 		$16.3K Sell
900
-900
-50% -$15.5K ﹤0.01% 6088
2025
Q4 		$35.2K Buy
1,800
+500
+38% +$9.47K ﹤0.01% 5888
2025
Q3 		$16.4K Buy
1,300
+300
+30% +$3.42K ﹤0.01% 6844
2025
Q2 		$9.52K Sell
1,000
-2,000
-67% -$22K ﹤0.01% 6747
2025
Q1 		$31.4K Buy
3,000
+1,500
+100% +$21.5K ﹤0.01% 5511
2024
Q4 		$35.3K Sell
1,500
-3,500
-70% -$104K ﹤0.01% 5304
2024
Q3 		$180K Buy
+5,000
New +$199K ﹤0.01% 3719
2024
Q2 		– Sell
-13,900
Closed -$395K – 6895
2024
Q1 		$395K Buy
13,900
+7,700
+124% +$174K ﹤0.01% 2963
2023
Q4 		$82.5K Buy
6,200
+3,200
+107% +$31.3K ﹤0.01% 4625
2023
Q3 		$26.9K Buy
+3,000
New +$32.3K ﹤0.01% 5642

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Group One Trading's DYN Position: Q2 2026 in Review

Group One Trading reduced its Dyne Therapeutics (DYN) stake by 65% in Q2 2026, selling an estimated $13K and leaving 373 shares worth $8.28K. The position accounts for ﹤0.01% of the portfolio, ranked #6515.

Group One Trading first reported a position in DYN in Q3 2023 and has held it in 11 quarters since. The position peaked at $1.05M in Q4 2023. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Group One Trading held 373 shares of Dyne Therapeutics worth $8.28K as of Q2 2026.
  • Group One Trading sold 700 Dyne Therapeutics shares in Q2 2026, an estimated $13K.
  • Dyne Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #6515 holding.
  • Group One Trading first reported a position in Dyne Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • Group One Trading's Dyne Therapeutics position peaked at $1.05M in Q4 2023.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.